文献速递肝病

核苷(酸)类似物停药后长期随访:HBsAg清除的不同模式

Long-Term Follow-Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg Loss.
PubMed 文献 · Aliment Pharmacol Ther · 2025-08-21

这项真实世界延伸研究随访了97例无肝硬化的HBeAg阴性慢性乙型肝炎患者,中位随访7年。停用核苷(酸)类似物后5、7、9年HBsAg累积清除率分别为10%、13%和22%;治疗结束时HBsAg水平较低、年龄较大及停药后HBV DNA峰值较低与HBsAg清除相关,未见肝功能失代偿或死亡,发生3例肝细胞癌。

要点

  • 停用核苷(酸)类似物后HBsAg清除率随随访延长而增加,但总体仍较低。
  • 治疗结束时HBsAg水平可预测HBsAg清除的可能性及时间模式。
  • ALT flare与HBsAg下降相关,部分病例随后出现延迟性HBsAg清除。

核心结论

  • 长期随访中功能性治愈率有所增加但仍较低,治疗结束时HBsAg水平强烈预测HBsAg清除的可能性和时机。

研究设计与样本

  • 真实世界延伸研究,随访来自一项前瞻性核苷(酸)类似物停药试验的97例无肝硬化HBeAg阴性慢性乙型肝炎患者,中位随访7年。

主要发现

  • 停药后5、7、9年HBsAg累积清除率分别为10%、13%和22%。
  • HBsAg清除与治疗结束时HBsAg水平较低(HR=0.28,p<0.001)、年龄较大(HR=1.14,p=0.005)及停药后HBV DNA峰值水平(OR=0.50,p=0.002)相关。
  • 治疗结束时HBsAg≤10 IU/mL者出现早期HBsAg清除(<96周)且无ALT flare;≥10 IU/mL者出现延迟HBsAg清除(≥96周),常伴随ALT flare(8例中5例)。
  • 未发生肝功能失代偿、肝移植或死亡,中位肝硬度未增加,诊断3例肝细胞癌(4.4/1000人年)。

关键数值与推荐

  • 治疗结束时HBsAg≤10 IU/mL与早期HBsAg清除(<96周)且无ALT flare相关。
  • 治疗结束时HBsAg≥10 IU/mL与延迟HBsAg清除(≥96周)相关,常伴随ALT flare。

临床怎么用

  • 对无肝硬化的HBeAg阴性慢性乙型肝炎患者,停用核苷(酸)类似物后应长期监测HBsAg、HBV DNA、ALT及肝细胞癌风险。
  • 治疗结束时HBsAg水平可用于预判停药后HBsAg清除的可能性及时间模式。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Discontinuing nucleos(t)ide analogues (NAs) may lead to functional cure (HBsAg loss) in selected patients with chronic hepatitis B (CHB). We evaluated the rates and predictors of HBsAg loss during long-term follow-up in a prospective cohort. METHODS: This real-world extension study followed participants from a prospective trial of NA discontinuation. All patients had HBeAg-negative CHB without cirrhosis. Efficacy outcomes (including HBsAg loss and decline) and safety outcomes [including hepatitis flare and hepatocellular carcinoma (HCC)] were evaluated. RESULTS: Amongst 97 participants (85% Asian), with a median follow-up of 7 years, the cumulative incidence of HBsAg loss was 10%, 13% and 22% at 5, 7 and 9 years after stopping NA. HBsAg loss was associated with a lower end-of-treatment (EOT) HBsAg level (HR = 0.28, p < 0.001), older age (HR = 1.14, p = 0.005) and peak off-treatment HBV DNA level (OR = 0.50, p = 0.002). Participants with EOT HBsAg level ≤ 10 IU/mL experienced early HBsAg loss (< 96 weeks) without ALT flares whilst those with EOT HBsAg level ≥ 10 IU/mL experienced late (≥ 96 weeks) HBsAg loss, often following ALT flares (5/8 cases). No cases of hepatic decompensation, liver transplantation or death occurred. Median liver stiffness did not increase. HCC was diagnosed in three individuals (4.4/1000 person-years). CONCLUSION: The rate of functional cure increased during long-term follow-up but remained low. EOT HBsAg strongly predicted the likelihood and timing of HBsAg loss. ALT flares were associated with HBsAg decline, and in some cases, with delayed HBsAg loss. TRIAL REGISTRATION: The clinical study was supported by the National Health and Medical Research Council of the study clinical trial ID is NCT02581033.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Hume SJ, Hall S, Burns G, et al. Long-Term Follow-Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg Loss. Aliment Pharmacol Ther. 2025. PMID: 40842267. doi:10.1111/apt.70332

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。